194 related articles for article (PubMed ID: 38384444)
1. Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3.
Hall J; Zhang Z; Bhattacharya S; Wang D; Alcantara M; Liang Y; Swiderski P; Forman S; Kwak L; Vaidehi N; Kortylewski M
Mol Ther Nucleic Acids; 2024 Mar; 35(1):102137. PubMed ID: 38384444
[TBL] [Abstract][Full Text] [Related]
2. Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3.
Hall J; Zhang Z; Wang D; Bhattacharya S; Alcantara M; Liang Y; Swiderski P; Forman S; Kwak L; Vaidehi N; Kortylewski M
bioRxiv; 2023 Aug; ():. PubMed ID: 37577590
[TBL] [Abstract][Full Text] [Related]
3. Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3.
Shih PC; Naganuma M; Tsuji G; Demizu Y; Naito M
Bioorg Med Chem; 2023 Nov; 95():117507. PubMed ID: 37922656
[TBL] [Abstract][Full Text] [Related]
4. Dual radiosensitization and anti-STAT3 anti-proliferative strategy based on delivery of gold nanoparticle - oligonucleotide nanoconstructs to head and neck cancer cells.
Zhang S; Gupta S; Fitzgerald TJ; Bogdanov AA
Nanotheranostics; 2018; 2(1):1-11. PubMed ID: 29291159
[TBL] [Abstract][Full Text] [Related]
5. B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.
Zhao X; Zhang Z; Moreira D; Su YL; Won H; Adamus T; Dong Z; Liang Y; Yin HH; Swiderski P; Pillai RK; Kwak L; Forman S; Kortylewski M
Mol Ther; 2018 Mar; 26(3):695-707. PubMed ID: 29433938
[TBL] [Abstract][Full Text] [Related]
6. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.
Kortylewski M; Moreira D
Cancer Immunol Immunother; 2017 Aug; 66(8):979-988. PubMed ID: 28214929
[TBL] [Abstract][Full Text] [Related]
7. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
[TBL] [Abstract][Full Text] [Related]
8. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.
Zhang Q; Hossain DM; Duttagupta P; Moreira D; Zhao X; Won H; Buettner R; Nechaev S; Majka M; Zhang B; Cai Q; Swiderski P; Kuo YH; Forman S; Marcucci G; Kortylewski M
Blood; 2016 Mar; 127(13):1687-700. PubMed ID: 26796361
[TBL] [Abstract][Full Text] [Related]
9. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
Lai AC; Toure M; Hellerschmied D; Salami J; Jaime-Figueroa S; Ko E; Hines J; Crews CM
Angew Chem Int Ed Engl; 2016 Jan; 55(2):807-10. PubMed ID: 26593377
[TBL] [Abstract][Full Text] [Related]
10. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.
Zhou H; Bai L; Xu R; Zhao Y; Chen J; McEachern D; Chinnaswamy K; Wen B; Dai L; Kumar P; Yang CY; Liu Z; Wang M; Liu L; Meagher JL; Yi H; Sun D; Stuckey JA; Wang S
J Med Chem; 2019 Dec; 62(24):11280-11300. PubMed ID: 31747516
[TBL] [Abstract][Full Text] [Related]
12. Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.
Mahan SD; Riching KM; Urh M; Daniels DL
Methods Mol Biol; 2021; 2365():151-171. PubMed ID: 34432243
[TBL] [Abstract][Full Text] [Related]
13. Targeted In Vivo Delivery of NF-κB Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy.
Zhang Z; Zhao X; Wang D; Moreira D; Su YL; Alcantara M; Swiderski P; Wong J; Hui S; Forman S; Kwak L; Kortylewski M
Mol Ther; 2021 Mar; 29(3):1214-1225. PubMed ID: 33248246
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer.
Jin J; Wu Y; Zhao Z; Wu Y; Zhou YD; Liu S; Sun Q; Yang G; Lin J; Nagle DG; Qin J; Zhang Z; Chen HZ; Zhang W; Sun S; Luan X
JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509291
[TBL] [Abstract][Full Text] [Related]
15. Uncovering PROTAC Sensitivity and Efficacy by Multidimensional Proteome Profiling: A Case for STAT3.
Suo Y; Du D; Chen C; Zhu H; Wang X; Song N; Lu D; Yang Y; Li J; Wang J; Luo Z; Zhou B; Luo C; Zhou H
J Med Chem; 2024 Mar; 67(6):4804-4818. PubMed ID: 38466231
[TBL] [Abstract][Full Text] [Related]
16. Bivalent Ligands for Protein Degradation in Drug Discovery.
Scheepstra M; Hekking KFW; van Hijfte L; Folmer RHA
Comput Struct Biotechnol J; 2019; 17():160-176. PubMed ID: 30788082
[TBL] [Abstract][Full Text] [Related]
17. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
18. Liposomal STAT3-Degrading PROTAC Prodrugs Promote Anti-Hepatocellular Carcinoma Immunity via Chemically Reprogramming Cancer Stem Cells.
Wang X; Zhao Y; Li X; Zhang Q; He J; Liu Y; Li M; Luo Z
Nano Lett; 2024 Apr; ():. PubMed ID: 38598369
[TBL] [Abstract][Full Text] [Related]
19. Inorganic kernel - Supported asymmetric hybrid vesicles for targeting delivery of STAT3-decoy oligonucleotides to overcome anti-HER2 therapeutic resistance of BT474R.
Shi K; Fang Y; Gao S; Yang D; Bi H; Xue J; Lu A; Li Y; Ke L; Lin X; Jin X; Li M
J Control Release; 2018 Jun; 279():53-68. PubMed ID: 29655990
[TBL] [Abstract][Full Text] [Related]
20. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
Singh H; Agrawal DK
Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
